Zosyn Is Cleared for Treatment Of Nosocomial Pneumonia

July 1, 1996

ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam) is now indicated for use in treating moderate to severe nosocomial pneumonia caused by piperacillin-resistant beta-lactamase-producing strains of Staphylococcus aureus. In a multicenter study of 300 patients with nosocomial pneumonia, the rate of clinical cure or improvement for Zosyn plus tobramycin was 74%, compared with 50% for cef-tazidime plus tobramycin, the company said.

ST. DAVIDS, Penn--Wyeth-Ayerst Laboratories' Zosyn (pipera-cillin/tazobactam)is now indicated for use in treating moderate to severe nosocomialpneumonia caused by piperacillin-resistant beta-lactamase-producingstrains of Staphylococcus aureus. In a multicenter study of 300patients with nosocomial pneumonia, the rate of clinical cureor improvement for Zosyn plus tobramycin was 74%, compared with50% for cef-tazidime plus tobramycin, the company said.